Clover's in-house, commercial-ready biologics manufacturing Changxing facility has a centrally-automated and flexible start-to-finish platform based on single-use technologies
Vaccine and biologic biotech, Clover Biopharmaceuticals, has announced that its wholly-owned subsidiary, Zhejiang Clover Biopharmaceutical, received a Pharmaceutical Manufacturing Permit from the Zhejiang Medical Products Administration.
The licence is for the production of Clover's protein-based COVID-19 vaccine candidate at its facility in Changxing, Zhejiang province, China (Changxing facility).
Clover's in-house, commercial-ready biologics manufacturing Changxing facility has a centrally-automated and flexible start-to-finish platform based on single-use technologies. The Changxing facility was designed to adhere to current Good Manufacturing Practices (cGMP) standards in accordance with NMPA, FDA, and EMA regulations.
At peak capacity, the Changxing facility will have the potential to annually produce more than one billion doses of antigen for Clover's COVID-19 vaccine candidate, SCB-2019.
Pending positive results from SPECTRA, Clover's global pivotal Phase 2/3 clinical COVID-19 vaccine candidate trial, the Company plans to submit conditional regulatory approval applications for SCB-2019 (CpG 1018/Alum) to the NMPA, EMA, and WHO thereafter. Pending conditional approval, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) which may occur as early as year-end 2021.
SCB-2019 (CpG 1018/Alum), Clover's COVID-19 vaccine candidate, is anticipated to potentially be one of the first protein-based COVID-19 vaccines commercialised globally through the COVAX Facility.
Employing the Trimer-Tag technology platform, Clover developed the SCB-2019 antigen, a stabilised trimeric form of the S-protein (S-Trimer) based on the original strain of the SARS-CoV-2 virus. Clover's COVID-19 vaccine candidate is the combination of SCB-2019 and two adjuvants, Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum).